First-in-Human Single Ascending and Multiple Dose of GLPG0634

NCT01179581 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: GLPG0634
DRUG: placebo
DRUG: GLPG0634
DRUG: placebo

Sponsor

Lakefront Biotherapeutics NV